

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Pawelek et al.;

Serial No.: Not yet assigned; continuation  
of appln. no. 09/358,052, filed July 21, 1999

Group Art Unit: Not yet assigned

Examiner: Not yet assigned

Filed: Concurrently herewith

Attorney Docket No.: 8002-081

For: VECTORS FOR THE DIAGNOSIS  
AND TREATMENT OF SOLID  
TUMORS INCLUDING  
MELANOMA

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references A01-A05; B01-B10; and C01-C90 listed on the attached revised form PTO 1449.

The above identified application is a continuation of U.S. Patent Application Serial No. 09/358,052 filed July 21, 1999 which is a continuation of 08/658,034 filed June 4, 1996. Pursuant to 37 C.F.R. §1.98(d), the Examiner is directed to the file of Application Serial No. 09/358,052 and Application Serial No. 08/658,034 for a copy of the listed references, which were all made of record in the prosecution history.


Identification of the above-listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to

use form PTO-1449, since that form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited".

Applicants request that the Examiner review all the references identified on the attached revised PTO Form 1449, and that they be made of record in the file history of the above-identified application.

Respectfully submitted,

Date: November 24, 2003



31,232

Geraldine F. Baldwin

(Reg. No.)

**PENNIE & EDMONDS LLP**

1155 Avenue of the Americas

New York, New York 10036-2711

(212) 790-9090

**EXPRESS MAIL NO: EV 159435376 US:****LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY DOCKET NO.

8002-081-999

APPLICATION NO

To be assigned

APPLICANT

Pawelek et al.

FILING DATE

Concurrently herewith

GROUP

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,436,727	03/13/84	Ribi			
	A02	5,021,234	06/04/91	Ehrenfeld			
	A03	5,344,762	09/06/94	Karapetian			
	A04	5,830,702	11/03/98	Portnoy et al.			
	A05	6,051,237	04/18/02	Paterson			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	B01	WO 92/11361	7-9-92	PCT			
	B02	WO 95/02048	1-19-95	PCT			
	B03	WO 96/11277	4-18-96	PCT			
	B04	0 564 121 A2	3/19/1993	EPO (Ref. No. 1 of Japanese Office Action)			
	B05	62145026 A	6/29/1987	Japan (Ref. No. 2 of Japanese Office Action)			
	B06	06298657A	10/25/1994	Japan (Ref. No. 3 of Japanese Office Action)			
	B07	01180830 A	7/18/1989	Japan (Ref. No. 4 of Japanese Office Action)			
	B08	63101328 A	6/05/1988	Japan (Ref. No. 5 of Japanese Office Action)			
	B09	WO 92/15689	9/17/1992	PCT (counterpart of 6-505158) (Ref. No. 6 of Japanese Office Action)			
	B10	WO 95/05835	3/02/1995	PCT (Ref. No. 7 of Japanese Office Action)			

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Tsujitani, S. et al., 1998 Cancer <u>61</u> : 1749-1753 Endoscopic Intratumoral Injection of OK-432 and Langerhans' Cells in Patients With Gastric Carcinoma
	C02	Okamoto M. et al., 2002 Anticancer Res. <u>22</u> : 3229-40 Enhancement of Anti-tumor Immunity by Lipoteichoic Acid-related Molecule Isolated from OK-432, a Streptococcal Agent, in Athymic Nude Mice Bearing Human Salivary Adenocarcinoma: Role of Natural Killer Cells
	C03	Hohmann et al., 1995, PNAS <u>92</u> (7): 2904-08 Macrophage-inducible expression of a model antigen in <i>Salmonella typhimurium</i> enhances immunogenicity
	C04	J. Adler, 1973, "A method of measuring chemotaxis and use of the method to determine optimum conditions for chemotaxis by <i>Escherichia coli</i> ", J Gen Microbiol <u>74</u> :77-91.
	C05	Alizadeh et al., 1994, "Apoptosis as a mechanism of cytolysis of tumor cells by a pathogenic free-living amoeba", Infect Immun <u>62</u> :1298-1303.
	C06	K. Bagshawe, 1995, "Antibody-directed enzyme prodrug therapy: A review", Drug Dev Res <u>34</u> :220-230.
	C07	Barry et al., 1995, "Protection against mycoplasma using expression library immunization", Nature <u>377</u> :632-635.
	C08	Barth and Morton, 1995, "The role of adjuvant therapy in melanoma management", Cancer <u>75</u> (Suppl.2):726-734.

EXPRESS MAIL NO: EV 159435376 US:

C09	R. Berggren, 1995, "Recombinant salmonella as an oral HIV vaccine", NIH project number 5 K01 AI01248-02.
C10	R. Bone, 1993, "Gram-negative sepsis: A dilemma of modern medicine", <u>Clin Microbiol Rev</u> 6:57-68.
C11	Bonnekoh et al., 1995, "Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer <i>in vivo</i> ", <u>J Invest Derm</u> 104:313-317.
C12	Carey et al., "Clostridial oncolysis in man", <u>Eur. J. Cancer</u> 3:37-46
C13	Carrier et al, 1996, "Expression of human IL-1 $\gamma$ in <i>Salmonella typhimurium</i> ; a model system for the delivery of recombinant therapeutic proteins <i>in vivo</i> ", <u>J. Immunology</u> 148:1176-1181
C14	Carswell et al., 1975, "An endotoxin-induced serum factor that causes necrosis of tumors", <u>Proc Natl Acad Sci</u> 72:3666-3669.
C15	Chabalgoity et al., 1996, "A <i>Salmonella typhimurium htrA</i> live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection", <u>Microbiol.</u> 19:791-801
C16	Christ et al., 1995, "E5531, a pure endotoxin antagonist of high potency", <u>Science</u> 268:80-83.
C17	J. Clements, 1995, "Attenuated salmonella as vaccine vectors", NIH project number 5 R01 AI 28835-06.
C18	Cunningham et al., 1992, "Actin-binding protein requirement for cortical stability and efficient locomotion", <u>Science</u> 255:325-327.
C19	R. Curtiss, 1995, "Biological containment of live bacterial vaccines", NIH project number 1 R41 AI38599-01.
C20	R. Curtiss, 1994, "Avirulent salmonella host-vector vaccine systems", NIH project number 1 R41 AI36585-01.
C21	E. Eidenstadt, 1987, "Analysis of mutagenesis", from <i>Escherichia coli</i> and <i>Salmonella typhimurium</i> , <u>Cellular and Molecular Biology</u> , Neidhardt et al. (ed.), pp. 1016-1033.
C22	Engelbart and Gericke, 1963, "Oncolysis by Clostridia. V. Transplanted tumors of the hamster", 1963, <u>Cancer Research</u> 24:239-243
C23	S. Falkow, 1991, "Bacterial entry into eukaryotic cells", <u>Cell</u> 65:1099-1102.
C24	Fox, et al., 1996, "Anaerobic bacteria as a delivery system for cancer gene therapy: <i>in vitro</i> activation of 5-fluorocytosine by genetically engineered Clostridia", <u>Gene Therapy</u> 3:173-178
C25	S. Friberg, 1993, "BCG in the treatment of superficial cancer of the bladder: A review", <u>Med Oncol Tumor Pharmacother</u> 10:31-36.
C26	J. Galan, 1995, "Novel salmonella antigen delivery vectors", NIH project number 5 R01 AI36520-02.
C27	Gericke and Engelbart, 1963, "Oncolysis by Clostridia. II. Experiments on a tumor spectrum with a variety of Clostridia in combination with heavy metal", <u>Cancer Research</u> 24:217-221
C28	P. Gulig, 1994, "Salmonella typhimurium virulence plasmid", NIH project number 5 R29 AI28421-05.
C29	Hall et al., 1994, "Induced regression of bovine papillomas by intralesional immunotherapy", <u>Therapeutic Immunol.</u> 1:319-324
C30	Han et al., 1967, "Salmonellosis in disseminated malignant diseases", <u>New Eng J Med</u> 276(11):1045-1052.
C31	R. Jain, 1994, "Barriers to Drug Delivery in Solid Tumors", <u>Scientific American</u> 7:58-65.
C32	Jones et al., 1992, "Invasion by <i>Salmonella typhimurium</i> is affected by the direction of flagellar rotation", <u>Infect Immun</u> 60:2475-2480.
C33	Karow and Georgopoulos, 1992, "Isolation and characterization of the <i>Escherichia coli msbB</i> gene, a multicopy suppressor of Null mutations in the high-temperature requirement gene <i>htrB</i> ", <u>J. Bacteriology</u> 174:702-710
C34	Klimpel et al., 1990, "Bacteria-infected fibroblasts have enhanced susceptibility to the cytotoxic action of tumor necrosis factor", <u>J Immunol</u> 145:711-717.
C35	Lee et al., 1992, "Identification of a <i>Salmonella typhimurium</i> invasion locus by selection for hyperinvasive mutants", <u>Proc Natl Acad Sci</u> 89:1847-1851.
C36	Lemmon et al., 1994, "Anaerobic bacteria as a gene delivery system to tumors", <u>Proc. Am. Assn. Cancer Research</u> 35:374 (Abstract 2231)
C37	M. Levine, 1995, "Recombinant and live oral salmonella typhi vaccines", NIH project number 5 R01 AI29471-06.
C38	Loppnow et al., 1990, "Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic <i>Rhodobacter capsulatus</i> LPS", <u>Infect Immun</u> 58:3743-3750.
C39	Lytvyn et al., 1992, "Comparison of the thymidine kinase genes from three entomopoxviruses", <u>J. Gen. Virol.</u> 73:3235-3240
C40	R. Macnab, 1992, "Genetics and biogenesis of bacterial flagella", <u>Ann Rev Genet</u> 26:131-158.
C41	Mahan et al., 1993, "Selection of bacterial virulence genes that are specifically induced in host tissues", <u>Science</u> 259:686-688.
C42	McLaughlin et al., 1979, "Synergistic activity of components of mycobacteria and mutant <i>Salmonella</i> in causing regression of line-10 tumors in guinea pigs", <u>Cancer Research</u> 39:1766-1771

C43	S. Michalek, 1994, "Genetically engineered oral vaccines and caries immunity", Abstract, NIH project number 5 R01 DE09081-05.
C44	Miller et al., 1989, "A two-component regulatory system ( <i>phoP phQ</i> ) controls <i>Salmonella typhimurium</i> virulence", <i>Proc Natl Acad Sci</i> <b>86</b> :5054-5058.
C45	V. Miller, 1995, "Entry into eukaryotic cells by salmonella and yersinia", NIH project number 5 K04 AI01230-02.
C46	Miller et al., 1992, "An unusual <i>pagC::TnphoA</i> mutation leads to an invasion and virulence-defective phenotype in <i>Salmonellae</i> ", <i>Infect Immun</i> <b>60</b> :3763-3770.
C47	Minton et al, 1995, "Chemotherapeutic tumour targeting using Clostridial spores", <i>FEMS Micro. Rev.</i> <b>17</b> :357-364
C48	Möse and Möse, 1963, "Oncolysis by Clostridia. I. Activity of <i>Clostridium butyricum</i> (M-55) and other nonpathogenic Clostridia against the Ehrlich carcinoma", <i>Cancer Research</i> <b>24</b> :212-216
C49	Mullen et al., 1992, "Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system", <i>PNAS (USA)</i> <b>89</b> :171-176
C50	Nauts et al., 1953, "A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man", <i>Acta Medica Scandinavica</i> <b>145</b> (Suppl. 276):1-105.
C51	Pan et al., 1995, "A recombinant <i>Listeria Monocytogenes</i> vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours", <i>Nature Medicine</i> <b>1</b> :471-477.
C52	Parker et al., "Effect of histiocytus infection and toxin on transplantable mouse tumors", 1947, <i>Pro. Soc. Exp. Biol. Med.</i> <b>16</b> :461-467
C53	Pawelek et al., 1995, "Macrophage characteristics of metastatic melanoma", <i>J Invest Dermatol</i> <b>104</b> :605 (Abstract 304).
C54	Pidherney et al., 1993, "In vitro and in vivo tumoricidal properties of a pathogenic free-living amoeba", <i>Cancer Letters</i> <b>72</b> :91-98.
C55	A. Pugsley, 1988, "Protein secretion across the outer membrane of gram-negative bacteria" In: <i>Protein Transfer and Organelle Biogenesis</i> , Dand and Robbins (eds.), Academic Press, Inc., Harcourt Brace Jovanovich, Publishers, San Diego, pp. 607-652.
C56	Raue and Cashel, 1975, "Regulation of RNA synthesis in <i>Escherichia coli</i> ", <i>Biochimica et Biophysica Acta</i> <b>383</b> :290-304
C57	Reinhard et al., 1950, "Chemotherapy of malignant neoplastic diseases", <i>JAMA</i> <b>142</b> (6):383-390.
C58	Saltzman et al., 1996, "Attenuated <i>Salmonella typhimurium</i> containig interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent", <i>Cancer Biotherapy and Radiopharmaceuticals</i> <b>11</b> :145-153
C59	Schafer et al., 1992, "Induction of a cellular immune response to a foreign antigen by a recombinant <i>Listeria monocytogenes</i> vaccine", <i>J. Immunol.</i> <b>149</b> :53
C60	Schlechte and Elbe, 1988, "Recombinant plasmid DNA variation of <i>Clostridium oncolyticum</i> - model experiments of cancerostatic gene transfer", <i>Zbl. Bakt. Hyg. A</i> <b>268</b> :347-356
C61	Schlechte et al., 1982, "Chemotherapy for tumours using Clostridial oncolysis, antibiotics and cyclophosphamide: model trial on the UVT 15264 tumour", <i>Arch. Geschwulstforsch</i> <b>52</b> :41-48
C62	Shaw et al., 1991, "The human dioxin-inducible NAD(P)H: quinone oxidoreductase cDNA-encoded protein expressed in COS-1 cells is identical to diaphorase 4", <i>Eur. J. Biochem.</i> <b>195</b> :171-176
C63	Sizemore et al., 1995, "Attenuated Shigella as a DNA Delivery Vehicle for DNA-Mediated Immunization", <i>Science</i> <b>270</b> :299-302.
C64	Slauch et al., 1994, "In vivo expression technology for selection of bacterial genes specifically induced in host tissues", <i>Meth Enzymol</i> <b>235</b> :481-492.
C65	Somerville et al., "A novel <i>Escherichia coli</i> lipid A mutant that produces an antiinflammatory lipopolysaccharide", <i>J. Clin. Invest.</i> <b>97</b> :359-365
C66	Sosnowski et al., 1994, "Complications of bacillus calmette-guerin (BCG) immunotherapy in superficial bladder cancer", <i>Comp Ther</i> <b>20</b> :695-701.
C67	Su et al., 1992, "Extracellular export of Shiga toxin B-subunit/haemolysin A (C-terminus) fusion protein expressed in <i>Salmonella typhimurium aroA</i> -mutant and stimulation of B-subunit specific antibody responses in mice", <i>Microbial Pathogenesis</i> <b>13</b> :465-476
C68	Takayma et al., 1989, "Diphosphoryl lipid A from <i>Rhodopseudomonas sphaeroides</i> ATCC 17023 blocks induction of cachectin in macrophages by lipopolysaccharide", <i>Infect Immun</i> <b>57</b> :1336-1338.

**EXPRESS MAIL NO: EV 159435376 US:**

C69	C	Thiele et al., 1963, "Oncolysis by Clostridia. III. Effects of Clostridia and chemotherapeutic agents on rodent tumors", <u>Cancer Research</u> 24:222-232
C70	C	Thiele et al., 1963, "Oncolysis by Clostridia. IV. Effect of nonpathogenic Clostridial spores in normal and pathological tissues", 1963, <u>Cancer Research</u> 24:234-238
C71	C	Tuomanen, 1993, "Subversion of leukocyte adhesion systems by respiratory pathogens", <u>Am Soc Microbiol</u> 59:292-296.
C72	C	Vinopal, 1987, "Selectable phenotypes", from <u>Escherichia coli and Salmonella typhimurium, Cellular and Molecular Biology</u> , Neidhardt et al. (ed.), pp. 990-1015.
C73	C	Wolfe et al., 1971, "Salmonellosis in patients with neoplastic disease", <u>Arch Intern Med</u> 128:547-554.
C74	C	Eisenstein et al., 1995, "Immunotherapy of a plasmacytoma with attenuated salmonella", <u>Medical Oncol.</u> 12(2):103-108.
C75	C	Bast RC Jr et al., "Antitumor activity of bacterial infection. II. effect of <i>Listeria monocytogenes</i> on growth of a guinea pig hepatoma", <u>J Natl Cancer Inst.</u> 1975 Mar;54(3):757-61
C76	I	Bast RC Jr, "Antitumor activity of bacterial infection. I. Effect of <i>Listeria monocytogenes</i> on growth of a murine fibrosarcoma", <u>J Natl Cancer Inst.</u> 1975 Mar;54(3):749-56.
C77	I	Hibbs et al., Role of activated macrophages in nonspecific resistance to neoplasia", <u>J Reticuloendothel Soc.</u> 1976 Sep;20(3):223-31
C78	I	Keller R, "Resistance to a non-immunogenic tumor, induced by <i>Corynebacterium parvum</i> or <i>Listeria monocytogenes</i> , is abrogated by anti-interferon gamma", <u>Int J Cancer.</u> 1990 Oct 15;46(4):687-90
C79	I	Koshimura et al., "On the streptolysin S synthesizing and anticancer activities of cell-free extract from living hemolytic streptococci", <u>Cncr Chemo.</u> 13:107
C80	I	Mizutani and Mitsuoka, 1980, "Inhibitory Effect of Some Intestinal Bacteria on Liver Tumorigenesis in Gnotobiotic C3H/He Male Mice," <u>Cancer Letter</u> 11:89-96.
C81	I	Murata et al., 1965, "Oncolytic Effect of <i>Proteus Mirabilis</i> Upon Tumor Bearing Animal," <u>Life Science</u> 4:1055-67.
C82	I	North et al., "T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites", <u>J Exp Med.</u> 1977 Feb 1;145(2):275-92
C83	I	Reilly CH, "Microbiology and cancer therapy: A Review", <u>Cancer Res.</u> 13(12): 821
C84	I	Youdim et al., "Resistance to tumor growth mediated by <i>Listeria monocytogenes</i> : collaborative and suppressive macrophage-lymphocyte interactions in vitro", <u>J Immunol.</u> 1976 Nov;117(5 Pt.2):1860-5.
C85	I	Youdim S, "Resistance to tumor growth mediated by <i>Listeria monocytogenes</i> . Destruction of experimental malignant melanoma by LM-activated peritoneal and lymphoid cells", <u>J Immunol.</u> 1976 Mar;116(3):579-84.
C86	I	Youdim S, et al., "Nonspecific suppression of tumor growth by an immune reaction to <i>Listeria monocytogenes</i> ", <u>J Natl Cancer Inst.</u> 1974 Jan;52(1):193-8
C87	I	Youdim et al., "Cooperation of immune lymphoid and reticuloendothelial cells during <i>Listeria monocytogenes</i> -mediated tumor immunity", <u>Cancer Res.</u> 1977 Apr;37(4):991-6
C88	I	Zinkernagel RM, "Early appearance of sensitized lymphocytes in mice infected with <i>Listeria monocytogenes</i> ", <u>J Immunol.</u> 1974 Feb;112(2):496-501
C89	I	Experimental Medicine, Vol 12, No. 15, (Supplementary) (1994) p. 1915-1919 (Ref. No. 8 of Japanese Office Action).
C90	I	Translation of Japanese Office Action mailed February 15, 2002 in connection with Japanese counterpart of U.S. application no. 08/658,034, now U.S. Patent No. 6,190,657, to which the present application claims priority.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.